Announcements Trials
Browse Landscape

Phase

Phase 2 6

Status

Completed 6

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 6

Sponsor

Cancer Type

Dermatologic 6

Conditions

Melanoma 98Carcinoma, Non-Small-Cell Lung 32Neoplasms 22Neoplasm Metastasis 14Carcinoma, Renal Cell 13Prostatic Neoplasms 12Lung Neoplasms 12Small Cell Lung Carcinoma 10Diabetes Mellitus, Insulin-Dependent, 12 10Pancreatic Neoplasms 7Uveal Melanoma 6Skin Neoplasms 6Ovarian Neoplasms 6Brain Neoplasms 6Advanced Cancer 6Squamous Cell Carcinoma of Head and Neck 5Sarcoma 5Mesothelioma 5Multiple Myeloma 4Lymphoma, Non-Hodgkin 4Lymphoma 4Kidney Neoplasms 4Hodgkin Disease 4Head and Neck Neoplasms 4Carcinoma, Transitional Cell 4Carcinoma, Merkel Cell 4Carcinoma, Hepatocellular 4Carcinoma 4Breast Neoplasms 4Various Advanced Cancer 3

Interventions

Ipilimumab 6pembrolizumab 5Nivolumab 5Dacarbazine 5CTLA-4 Antigen 4Carboplatin 3Bevacizumab 3relatlimab 2aflibercept 2Temozolomide 2Ranibizumab 2Radiosurgery 2Paclitaxel 2Lenalidomide 2Immunoglobulin G 2Embolization, Therapeutic 2Disulfides 2Cyclophosphamide 2Colony-Stimulating Factors 2Albumin-Bound Paclitaxel 2AZD 6244 2130-nm albumin-bound paclitaxel 2utomilumab 1ulixertinib 1trametinib 1tebentafusp 1sotrastaurin 1sargramostim 1poly ICLC 1pasireotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Has results × Uveal Melanoma × Ipilimumab × Clear all
NCT03070392 2026-03-17

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

Immunocore Ltd

Phase 2 Completed
378 enrolled 15 charts 1 FDA
Dermatologic

Uveal Melanoma, Melanoma

NCT03472586 2025-04-24

Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver

Thomas Jefferson University

Phase 2 Completed
14 enrolled 8 charts
Dermatologic

Uveal Melanoma

NCT01585194 2024-07-09

Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

M.D. Anderson Cancer Center

Phase 2 Completed
67 enrolled 12 charts
Dermatologic

Uveal Melanoma

NCT02519322 2024-04-05

Neoadjuvant and Adjuvant Checkpoint Blockade

M.D. Anderson Cancer Center

Phase 2 Completed
53 enrolled 10 charts
Dermatologic

Uveal Melanoma, Melanoma

NCT00084656 2022-04-14

Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma

Bristol-Myers Squibb

Phase 2 Completed
77 enrolled 13 charts
Dermatologic

Uveal Melanoma, Melanoma

NCT02158520 2020-01-21

Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery

Academic and Community Cancer Research United

Phase 2 Completed
24 enrolled 10 charts
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡